
Biodesix BDSX
$ 12.14
-9.13%
Quarterly report 2025-Q3
added 11-03-2025
Biodesix Operating Income 2011-2026 | BDSX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Biodesix
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -34.5 M | -41.3 M | -50.6 M | -40.9 M | -22.9 M | -26.7 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -22.9 M | -50.6 M | -36.2 M |
Quarterly Operating Income Biodesix
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.05 M | -9.72 M | -9.14 M | - | -8.59 M | -8.24 M | -11 M | - | -7.17 M | -10.9 M | -16.4 M | - | -10.6 M | -11.6 M | -14.5 M | - | -13.1 M | -10.6 M | -5.58 M | - | -6.24 M | -5.62 M | -8.42 M | - | -9.03 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -5.58 M | -16.4 M | -9.66 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
-797 M | $ 19.89 | 10.93 % | $ 211 M | ||
|
Agilent Technologies
A
|
1.35 B | $ 120.39 | 2.46 % | $ 36.6 B | ||
|
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | ||
|
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | ||
|
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | ||
|
CareDx, Inc
CDNA
|
-30.8 M | $ 17.63 | 4.75 % | $ 939 M | ||
|
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | ||
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
-50.2 M | $ 1.38 | -4.83 % | $ 1.84 M | ||
|
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | ||
|
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
8.67 M | $ 24.37 | 3.57 % | $ 677 M | ||
|
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | ||
|
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
25.2 M | $ 179.31 | 0.54 % | $ 8.89 B | ||
|
Interpace Biosciences
IDXG
|
4.08 M | $ 2.2 | - | $ 9.73 M | ||
|
Danaher Corporation
DHR
|
4.69 B | $ 198.61 | 1.4 % | $ 142 B | ||
|
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
-833 M | $ 130.32 | 2.65 % | $ 20.7 B | ||
|
Medpace Holdings
MEDP
|
535 M | $ 520.0 | 3.74 % | $ 15 B | ||
|
Fulgent Genetics
FLGT
|
-73.9 M | $ 16.02 | 4.71 % | $ 484 M | ||
|
Koninklijke Philips N.V.
PHG
|
553 M | $ 29.09 | 1.89 % | $ 20 B | ||
|
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | ||
|
Guardant Health
GH
|
-437 M | $ 86.4 | 5.1 % | $ 10.8 B | ||
|
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | ||
|
Myriad Genetics
MYGN
|
-387 M | $ 4.91 | 6.97 % | $ 455 M | ||
|
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.88 | 1.05 % | $ 93.5 K | ||
|
Biomerica
BMRA
|
-5.14 M | $ 2.1 | 0.96 % | $ 4.82 M | ||
|
Senseonics Holdings
SENS
|
-68.3 M | $ 6.75 | 0.45 % | $ 282 M | ||
|
ICON Public Limited Company
ICLR
|
1.1 B | $ 113.06 | 2.44 % | $ 9.33 B | ||
|
NeoGenomics
NEO
|
-116 M | $ 8.35 | 4.38 % | $ 1.07 B | ||
|
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 268.87 | 1.78 % | $ 22.4 B | ||
|
Celcuity
CELC
|
-172 M | $ 120.85 | 0.37 % | $ 5.65 B | ||
|
Neogen Corporation
NEOG
|
-1.06 B | $ 9.61 | 5.14 % | $ 2.08 B | ||
|
Lantheus Holdings
LNTH
|
311 M | $ 82.74 | 1.31 % | $ 5.58 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 194.16 | 0.65 % | $ 21.6 B | ||
|
Natera
NTRA
|
-541 M | $ 214.64 | 6.31 % | $ 21.1 B | ||
|
ENDRA Life Sciences
NDRA
|
-5.76 M | $ 4.96 | -4.43 % | $ 3.9 M | ||
|
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | ||
|
National Research Corporation
NRC
|
22.6 M | $ 17.04 | 1.34 % | $ 381 M | ||
|
Organovo Holdings
ONVO
|
-12.6 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M |